PNC Financial Services Group
CERE

PNC Financial Services Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

PNC Financial Services Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$654 – 4964
2024
Q2 		$654 Buy
16
+4
+33% +$167 ﹤0.01% 4494
2024
Q1 		$507 Sell
12
-6,488
-100% -$273K ﹤0.01% 4496
2023
Q4 		$276K Sell
6,500
-3,006
-32% -$86.4K ﹤0.01% 1920
2023
Q3 		$208K Buy
9,506
+3,866
+69% +$96.7K ﹤0.01% 2094
2023
Q2 		$179K Buy
+5,640
New +$173K ﹤0.01% 2280

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

PNC Financial Services Group's CERE Position: Q3 2024 in Review

PNC Financial Services Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 16 shares — an estimated $654 sold.

PNC Financial Services Group first reported a position in CERE in Q2 2023 and held it in 5 quarters. The position peaked at $276K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • PNC Financial Services Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 16 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $654.
  • PNC Financial Services Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
  • PNC Financial Services Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $276K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.